Launching a drug development company with novel technology from academia
Our corporate group has worked with hundreds of entrepreneurs at this stage to help them optimally and efficiently select and form the appropriate legal entity
University Collaborations
Not-for-profit research institutions are strong sources and drivers of innovation.
Overview
Collaborating with universities, research hospitals and foundations is an increasingly important way for companies to accelerate value creation – whether the field is life science, healthcare IT, medical devices or engineering technology.
These relationships are challenging to structure, and there’s often great pressure to conclude an agreement quickly and with modest cost.
You want to be sure your critical interests are protected, and to ensure that your contract can withstand future due diligence by potential investors, underwriters and commercial partners.
Experience
At Faber, we have an extensive practice devoted to collaborations between industry and academic institutions. Our 2000+ clients have included public and venture-backed companies, investors, academic researchers and entrepreneurs, foundations and other not-for-profit entities, and some of the most prestigious universities in the U.S. and Europe.
We regularly work with startups seeking to in-license their core technology, as well as more established companies looking for complementary discovery and development expertise. We have helped academic institutions negotiate intellectual property licenses, organize consortiums and optimize their investments in companies that are further developing technology invented in the institutions’ labs.
Our transactional experience includes:
In-licensing of compounds, processes and platform technologies developed by academia and other nonprofits
Sponsored research
Academic consulting
Materials transfer arrangements
Research collaborations
Clinical development collaborations
Consortiums
A Devoted Team
We have more professionals focused on this area than you’re likely to find anywhere else, including lawyers and contracts specialists who have devoted their entire careers to these collaborations, and have worked in-house in these institutions. We recognize that the cultures of these institutions are unique, leading to profoundly different approaches to contracting. And we know how to navigate the negotiation in order to get the job done efficiently, without sacrificing important details. Based on our significant market knowledge, we can advise you on prioritizing goals in negotiations and efficiently finding common ground.
Related Transactions
Ipsen Bioscience Inc. + Université de Montréal
Research and Option Agreement to Acquire Exclusive LicenseFaber assisted Ipsen with a Research and Option Agreement under which Université de Montréal would conduct a lead optimization program on a high-value oncology program. Upon exercise of the option at the end of the research term, Ipsen would acquire an exclusive license for the worldwide rights to the program
Press Release
Phenex Pharmaceuticals AG + Gilead Sciences
Program SaleSale of Phenex’s FXR program for the treatment of non-alcoholic steatohepatitis (NASH) and other liver diseases
